Binnopharm may become leading player in Russian OTC drugs market

6 December 2016

Russian drugmaker Binnopharm, which is owned by the local financial conglomerate AFK Systema, may become a leading player in the Russian market of over-the-counter (OTC) drugs in the coming years, reports The Pharma Letter’s local correspondent.

This is the expected result of Binnopharma’s acquisition of its local competitor Alpharm, a company whose portfolio of drugs includes an antiviral Kipferon drug, as well as Prostopin, a drug which is used in the treatment of hemorrhoids and prostatitis.

Kipferon currently remains the fourth largest interferon-based immunomodulator in terms of sales in the market segment, the value of which is estimated at about 3 billion roubles (~$47 million).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK